1-2 of 2
Elizabeth Cull
Close
Sort by
Journal Articles

A Phase 1a/b Dose Escalation Study of the Mutation Agnostic BTK/FLT3 Inhibitor Luxeptinib (CG-806) in Patients with Relapsed or Refractory B-Cell Malignancies

Felipe Samaniego, John M. Burke, Daruka Mahadevan, Mohamad Cherry, Ahad A. Sadiq, M. Zach Koontz, Jose C. Villasboas, Erin Reid, Elizabeth Cull, Victor Priego, Lindsey E. Roeker, Patrick Cobb, Jason Melear, Paul Conkling, David Cosgrove, Hongying Zhang, Nasrin Rastgoo, Khalid Benbatoul, Donna Nguyen Haney, Yuying Jin, Jotin Marango, Stephen B Howell, William G Rice, Rafael Bejar
Journal: Blood
Blood (2021) 138 (Supplement 1): 1355.
https://doi.org/10.1182/blood-2021-148827
Published: 2021
Journal Articles

Administration of All-Trans Retinoic Acid (ATRA) to Newly Diagnosed Patients (pts) with Acute Promyelocytic Leukemia (APL) Is Delayed Even At Experienced Centers and Associated with An Increased Early Death Rate (EDR): A Retrospective Analysis of 205 Pts

Jessica K. Altman, MD, Alfred Rademaker, PhD, Elizabeth Cull, MD, Bing Bing Weitner, MS, Yishai Ofran, MD, Todd L. Rosenblat, MD, Augustin Haidau, MD, Jae H. Park, MD, Sharona Ram, MD, James Orsini, MD, Sonia Sandhu, MD, Rose Catchatourian, MD, Steven M. Trifilio, RPh, Nelly G. Adel, PharmD, BCOP, BCPS, Olga Frankfurt, MD, George Mallios, MD, Tony Deblasio, MS, Joseph G. Jurcic, MD, Stephen Nimer, MD, Jacob M. Rowe, MD, Dan Douer, MD, Martin S. Tallman, MD
Journal: Blood
Blood (2011) 118 (21): 942.
https://doi.org/10.1182/blood.V118.21.942.942
Published: 2011